Cowen & Co. Sticks to Their Buy Rating for Krystal Biotech (KRYS)

By Jason Carr

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Krystal Biotech (KRYSResearch Report). The company’s shares closed last Monday at $43.68.

According to, Baral is a 5-star analyst with an average return of 21.7% and a 46.5% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Milestone Pharmaceuticals, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on Krystal Biotech is a Strong Buy with an average price target of $66.67, representing a 57.9% upside. In a report issued on October 29, William Blair also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $51.67 and a one-year low of $16.82. Currently, Krystal Biotech has an average volume of 155.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.